GlassScriptPhysician profile
Kari R Clouse
NPI 1962636944
$11,546.66
in general payments reported to CMS, 2019-2025
55 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $1,204 · 2021: $1,927 · 2022: $1,947 · 2023: $1,639 · 2024: $1,904 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,695 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,694.58 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,743.83 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Lilly USA, LLC | $1,181.82 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $824.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $793.64 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $779.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $699.37 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $634.75 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $536.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $412.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $307.10 | 2019-2024 | Xarelto |
| Allergan, INC. | $268.41 | 2019-2020 | |
| Zyla Life Sciences, INC. | $262.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $242.50 | 2022-2025 | |
| Abbott Laboratories | $233.73 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lundbeck LLC | $187.02 | 2020-2025 | Rexulti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Clouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.